{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:36:31Z","timestamp":1791549391666,"version":"4.3.4"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jceh.2026.103608","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:19:04Z","timestamp":1783628344000},"page":"103608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Digital Pathology\u2013Enabled Artificial Intelligence for Fibrosis Assessment in Metabolic Dysfunction\u2013Associated Steatohepatitis: Needs, Current Progress, and Barriers"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9669-3961","authenticated-orcid":false,"given":"Archana","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2026.103608_bib1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/biomedicines13040846","article-title":"Digital pathology tailored for assessment of liver biopsies","volume":"13","author":"Onoiu","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.jceh.2026.103608_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cld.2023.01.017","article-title":"Role of liver biopsy in clinical trials and clinical management of nonalcoholic fatty liver disease","volume":"27","author":"Goodman","year":"2023","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2026.103608_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep4.1079","article-title":"Clinical endpoints and adaptive clinical trials in precirrhotic non-alcoholic steatohepatitis: facilitating development approaches for an emerging epidemic","volume":"1","author":"Filozof","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jceh.2026.103608_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/joim.13030","article-title":"Artificial intelligence as the next step towards precision pathology","volume":"288","author":"Acs","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.jceh.2026.103608_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41746-024-01106-8","article-title":"Artificial intelligence in digital pathology: a systematic review and meta-analysis of diagnostic test accuracy","volume":"7","author":"McGenity","year":"2024","journal-title":"npj Digit Med"},{"key":"10.1016\/j.jceh.2026.103608_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/diagnostics14040388","article-title":"The use of artificial intelligence in the liver histopathology field: a systematic review","volume":"14","author":"Grignaffini","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.jceh.2026.103608_bib10","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3390\/diagnostics13101799","article-title":"Artificial intelligence-based opportunities in liver Pathology-A systematic review","volume":"13","author":"Allaume","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.jceh.2026.103608_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11154-021-09681-x","article-title":"Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : a systematic review","volume":"23","author":"Li","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jceh.2026.103608_bib12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s12325-024-02781-5","article-title":"Artificial intelligence in liver diseases: recent advances","volume":"41","author":"Lu","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jceh.2026.103608_bib13","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib14","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly Obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of non-alcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2023.10.015","article-title":"Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2026.103608_bib18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","article-title":"Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD","volume":"76","author":"Brunt","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/cancers17050722","article-title":"Revolutionizing MASLD: how artificial intelligence is shaping the future of liver care","volume":"17","author":"Pugliese","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jceh.2026.103608_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2026.103608_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/d41573-024-00051-1","article-title":"NASH field celebrates \u2018hurrah moment\u2019 with a first FDA drug approval for the liver disease","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jceh.2026.103608_bib23","article-title":"Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment","year":"2018","journal-title":"Guidance for industry [draft guidance]"},{"key":"10.1016\/j.jceh.2026.103608_bib24","series-title":"Reflection Paper on Regulatory Requirements for the Development of Medicinal Products for Chronic Non 6 Infectious Liver Diseases","year":"2018"},{"key":"10.1016\/j.jceh.2026.103608_bib25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert panel review to compare FDA and EMA guidance on drug development and endpoints in non-alcoholic steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2026.103608_bib26","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2026.103608_bib28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2026.103608_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib30","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Liver forum case definitions working group. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.32475","article-title":"Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score","volume":"76","author":"Pai","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib32","article-title":"The elucidating pathways of steatohepatitis (EPoS) staging system: a reproducible 7-tiered fibrosis scoring system in MASLD","volume":"8","author":"Tiniakos","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2026.103608_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41575-023-00843-7","article-title":"Digital pathology for non-alcoholic steatohepatitis assessment","volume":"21","author":"Sanyal","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib34","article-title":"Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: data from a phase 3 study","volume":"8","author":"Sanyal","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jceh.2026.103608_bib35","article-title":"The Asian Pacific association of the study of the liver expert survey on artificial intelligence-assisted reporting of liver histopathology in metabolic dysfunction associated fatty liver disease","volume":"13","author":"Elangovan","year":"2026","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2026.103608_bib36","article-title":"Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials","author":"Lackner","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00795-024-00395-y","article-title":"Liver fibrosis analysis using digital pathology","volume":"57","author":"Miyaaki","year":"2024","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.jceh.2026.103608_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/jpi.jpi_38_20","article-title":"Display characteristics and their impact on digital pathology: a current review of Pathologists' Future \"Microscope\"","volume":"11","author":"Abel","year":"2020","journal-title":"J Pathol Inform"},{"key":"10.1016\/j.jceh.2026.103608_bib39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.5331","article-title":"Computational pathology definitions, best practices, and recommendations for regulatory guidance: a white paper from the digital pathology association","volume":"249","author":"Abels","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.jceh.2026.103608_bib40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5858\/arpa.2018-0343-RA","article-title":"A practical guide to whole slide imaging: a white paper from the digital pathology association","volume":"143","author":"Zarella","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jceh.2026.103608_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.5858\/arpa.2014-0073-OA","article-title":"Validation of multiple whole slide imaging scanners based on the guideline from the college of American pathologists pathology and laboratory quality center","volume":"139","author":"Thrall","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jceh.2026.103608_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23905-3","article-title":"Deep learning-based quantification of NAFLD\/NASH progression in human liver biopsies","volume":"12","author":"Heinemann","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2026.103608_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13000-023-01375-z","article-title":"Artificial intelligence in diagnostic pathology","volume":"18","author":"Shafi","year":"2023","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jceh.2026.103608_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.103145","article-title":"Artificial intelligence in liver pathology: precision histology for accurate diagnoses","volume":"15","author":"Sanyal","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib45","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1002\/hep.32087","article-title":"A machine learning approach to liver histological evaluation predicts clinically significant portal hypertension in NASH cirrhosis","volume":"74","author":"Bosch","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib46","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s13244-018-0639-9","article-title":"Convolutional neural networks: an overview and application in radiology","volume":"9","author":"Yamashita","year":"2018","journal-title":"Insights Imaging"},{"issue":"4","key":"10.1016\/j.jceh.2026.103608_bib47","doi-asserted-by":"crossref","DOI":"10.1117\/1.3183811","article-title":"Fibro-C-Index: comprehensive, morphology-based quantification of liver fibrosis using second harmonic generation and two-photon microscopy","volume":"14","author":"Tai","year":"2009","journal-title":"J Biomed Opt"},{"issue":"6","key":"10.1016\/j.jceh.2026.103608_bib48","doi-asserted-by":"crossref","DOI":"10.1117\/1.3041159","article-title":"Nonlinear optical microscopy: use of second harmonic generation and two-photon microscopy for automated quantitative liver fibrosis studies","volume":"13","author":"Sun","year":"2008","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.jceh.2026.103608_bib49","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/hep.29090","article-title":"Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/2632010X231162317","article-title":"Second-harmonic generated quantifiable fibrosis parameters provide signatures for disease progression and regression in nonalcoholic fatty liver disease","volume":"16","author":"Ng","year":"2023","journal-title":"Clin Pathol"},{"key":"10.1016\/j.jceh.2026.103608_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2014.02.015","article-title":"qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients","volume":"61","author":"Xu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib52","article-title":"Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation\/two-photon excitation fluorescence microscopy","volume":"7","author":"Field","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2026.103608_bib53","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/cjp2.227","article-title":"Reliable computational quantification of liver fibrosis is compromised by inherent staining variation","volume":"7","author":"Astbury","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.jceh.2026.103608_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081772","article-title":"Imaging collagen in scar tissue: developments in second harmonic generation microscopy for biomedical applications","volume":"18","author":"Mosta\u00e7o-Guidolin","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jceh.2026.103608_bib55","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jhep.2025.04.026","article-title":"The emerging role of second harmonic generation\/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials","volume":"83","author":"Neuschwander-Tetri","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.31750","article-title":"A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH","volume":"74","author":"Taylor-Weiner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib57","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/s41591-024-03172-7","article-title":"AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases","volume":"30","author":"Iyer","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2026.103608_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-024-03301-2","article-title":"Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Pulaski","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2026.103608_bib59","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/bioinformatics\/btp699","article-title":"Bisque: a platform for bioimage analysis and management","volume":"26","author":"Kvilekval","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jceh.2026.103608_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)01214-4","article-title":"Evaluation of the performance of a novel digital pathology method for the continuous quantification of steatosis, ballooning and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH","volume":"77","author":"Petitjean","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib61","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1038\/s41598-024-55438-2","article-title":"Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model","volume":"14","author":"Kostadinova","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2026.103608_bib62","article-title":"Exploratory analyses of NASH histology using CRN scores derived from a multi-stain machine learning method","volume":"76","author":"Abel","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib63","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41374-019-0315-9","article-title":"Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD\/NASH","volume":"100","author":"De Rudder","year":"2020","journal-title":"Lab Invest"},{"key":"10.1016\/j.jceh.2026.103608_bib64","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1111\/liv.16092","article-title":"Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology","volume":"44","author":"Naoumov","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2026.103608_bib73","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jhep.2022.06.018","article-title":"Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH","volume":"77","author":"Naoumov","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib65","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2022.05.027","article-title":"Artificial intelligence improves pathologist agreement for fibrosis scores in nonalcoholic steatohepatitis patients","volume":"21","author":"Soon","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib66","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2024.11.032","article-title":"Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH","volume":"82","author":"Abdurrachim","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib67","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1111\/liv.16025","article-title":"AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: an exploratory study","volume":"44","author":"Yuan","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2026.103608_bib68","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib69","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/liv.16062","article-title":"Outcome prediction in metabolic dysfunction-associated steatotic liver disease using stain-free digital pathological assessment","volume":"44","author":"Kendall","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2026.103608_bib70","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/apt.17363","article-title":"Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis","volume":"57","author":"Noureddin","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2026.103608_bib71","article-title":"Repeatability and reproducibility of artificial imaging-based digital pathology for the evaluation of liver fibrosis","author":"Ren","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib72","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/apt.17635","article-title":"AutoFibroNet: a deep learning and multi-photon microscopy-derived automated network for liver fibrosis quantification in MAFLD","volume":"58","author":"Zhan","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2026.103608_bib74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/HEP.0000000000000723","article-title":"Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis","volume":"80","author":"Ratziu","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103608_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1480866","article-title":"Role of artificial intelligence in staging and assessing of treatment response in MASH patients","volume":"11","author":"Akpinar","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.jceh.2026.103608_bib76","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/kjm2.12850","article-title":"Development of a diagnostic support system for the fibrosis of nonalcoholic fatty liver disease using artificial intelligence and deep learning","volume":"40","author":"Preechathammawong","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jceh.2026.103608_bib77","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.dld.2023.08.048","article-title":"Special interest group (SIG) artificial intelligence and liver disease; Italian association for the study of liver (AISF). Artificial intelligence and liver: opportunities and barriers","volume":"55","author":"Balsano","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2026.103608_bib78","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/jgh.15415","article-title":"Artificial intelligence in precision medicine in hepatology","volume":"36","author":"Su","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103608_bib79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1126\/scirobotics.aay7120","article-title":"XAI-Explainable artificial intelligence","volume":"4","author":"Gunning","year":"2019","journal-title":"Sci Robot"},{"key":"10.1016\/j.jceh.2026.103608_bib80","article-title":"From what to why, the growing need for a focus shift toward explainability of AI in digital pathology","volume":"12","author":"Border","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.jceh.2026.103608_bib81","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41591-021-01461-z","article-title":"AI in medicine must be explainable","volume":"27","author":"Kundu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jceh.2026.103608_bib82","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ajpath.2020.10.018","article-title":"Challenges in the development, deployment, and regulation of artificial intelligence in anatomic pathology","volume":"191","author":"Cheng","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jceh.2026.103608_bib83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PAP.0000000000000264","article-title":"Explainable AI (xAI) for anatomic pathology","volume":"27","author":"Tosun","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.jceh.2026.103608_bib84","unstructured":"Kaczmarzyk JR, Saltz JH, Koo PK. Explainable AI for computational pathology identifies model limitations and tissue biomarkers. ArXiv [Preprint]. 2024:arXiv:2409.03080v2. PMID: 39279830; PMCID: PMC11398542."},{"key":"10.1016\/j.jceh.2026.103608_bib85","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s44222-023-00096-8","article-title":"Artificial intelligence for digital and computational pathology","volume":"1","author":"Song","year":"2023","journal-title":"Nat Rev Bioeng"},{"key":"10.1016\/j.jceh.2026.103608_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.cosrev.2025.100863","article-title":"Exploring transparency in pathological image analysis: a comprehensive review of explainable artificial intelligence (XAI) techniques","volume":"60","author":"Yuan","year":"2026","journal-title":"Comput Sci Rev"},{"key":"10.1016\/j.jceh.2026.103608_bib87","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14737159.2025.2581687","article-title":"Digital pathology and AI: enhancing molecular diagnostics in low- and middle-income countries","volume":"25","author":"Rahman","year":"2025","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jceh.2026.103608_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1146075","article-title":"Sustainable development goals applied to digital pathology and artificial intelligence applications in low- to middle-income countries","volume":"10","author":"Piya","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.jceh.2026.103608_bib89","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13000-023-01352-6","article-title":"A suggested way forward for adoption of AI-Enabled digital pathology in low resource organizations in the developing world","volume":"18","author":"Zehra","year":"2023","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jceh.2026.103608_bib90","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/diagnostics15081032","article-title":"Stain normalization of histopathological images based on deep learning: a review","volume":"15","author":"Xu","year":"2025","journal-title":"Diagnostics"},{"key":"10.1016\/j.jceh.2026.103608_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2023.100261","article-title":"Real-world implementation of digital pathology: results from an intercontinental survey","volume":"103","author":"Pinto","year":"2023","journal-title":"Lab Invest"},{"key":"10.1016\/j.jceh.2026.103608_bib92","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/hep.30986","article-title":"qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:44:22Z","timestamp":1791323062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688326001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0973688326001404"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103608","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digital Pathology\u2013Enabled Artificial Intelligence for Fibrosis Assessment in Metabolic Dysfunction\u2013Associated Steatohepatitis: Needs, Current Progress, and Barriers","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103608"}}